Physician profile
Amber Ryan
NPI 1003422676
$3,230.47
in general payments reported to CMS, 2019-2025
14 companies · $80.97 in 2025
The $80.97 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.27 · 2022: $38.20 · 2023: $2,908 · 2024: $187 · 2025: $80.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,168 · Food and Beverage: $981 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,168.29 |
| Food and Beverage | $980.71 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,745.88 | 2021-2024 | Interstim |
| Aspira Women'S Health INC | $82.13 | 2023 | Ova1 |
| Astellas Pharma US INC | $80.69 | 2022-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $54.35 | 2023-2025 | |
| Boston Scientific Corporation | $38.00 | 2025 | General - Therapies |
| Abiomed | $36.33 | 2024 | Impella |
| Abbvie INC. | $31.24 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $31.17 | 2024 | Gardasil, Gardasil 9 |
| Smith+Nephew, INC. | $29.57 | 2023 | Pico |
| Hologic Sales and Service, LLC | $28.24 | 2023 | Aptima |
| Organon LLC | $23.52 | 2024 | |
| Coopersurgical, INC. | $20.38 | 2025 | Paragard T 380a |
| Novo Nordisk INC | $14.91 | 2024 | Wegovy |
| Exeltis, USA INC. | $14.06 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.